Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis

被引：0
|
作者：
Schett, G. [1 ]
Mease, P. J. [2 ,3 ]
Kavanaugh, A. [4 ]
Adebajo, A. O. [5 ]
Gomez-Reino, J. J. [6 ]
Wollenhaupt, J. [7 ]
Cutolo, M. [8 ]
Lespessailles, E. [9 ]
Shah, K.
Hu, C.
Stevens, R.
Edwards, C. [10 ]
Birbara, C. [11 ]
机构：
[1] Univ Erlangen Nurnberg, D-91054 Erlangen, Germany
[2] Swedish Med Ctr, Seattle, WA USA
[3] Univ Washington, Sch Med, Seattle, WA USA
[4] Univ Calif San Diego, San Diego, CA 92103 USA
[5] Univ Sheffield, Sheffield, S Yorkshire, England
[6] Hosp Clin Univ, Santiago, Spain
[7] Schon Klin Hamburg Eilbek, Hamburg, Germany
[8] Univ Genoa, Genoa, Italy
[9] Univ Orleans, Orleans, France
[10] Southampton Univ Hosp, Southampton, Hants, England
[11] Univ Massachusetts, Sch Med, Worcester, MA USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P012
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [21] COMPARISON OF THE EFFICACY AND SAFETY OF TOFACITINIB AND APREMILAST IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Lee, Young Ho
    Song, Gwan Gyu
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1275 - 1276
  • [22] Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
    Gwan Gyu Song
    Young Ho Lee
    Clinical Drug Investigation, 2019, 39 : 421 - 428
  • [23] Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials
    Gladman, Dafna D.
    Kavanaugh, Arthur
    Gomez-Reino, Juan J.
    Wollenhaupt, Juergen
    Cutolo, Maurizio
    Schett, Georg
    Lespessailles, Eric
    McIlraith, Melissa
    Hu, ChiaChi
    Edwards, Christopher J.
    Birbara, Charles A.
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [24] Assessment of Disability Levels in a Cohort of 1,489 Patients with Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data from Three Phase III, Randomized, Controlled Trials
    Mease, Philip J.
    Wollenhaupt, Juergen
    Hall, Stephen
    van Den Bosch, Filip
    Lespessailles, Eric
    McIlraith, Melissa
    Teng, Lichen
    Edwards, Christopher J.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [25] Correction to: Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
    Gwan Gyu Song
    Young Ho Lee
    Clinical Drug Investigation, 2019, 39 : 701 - 701
  • [26] Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis of two phase randomized controlled trials (ESTEEM 1 and 2)
    Reich, K.
    Papp, K.
    Gordon, K.
    Griffiths, C.
    Chimenti, S.
    Lopez-Estebaranz, J. L.
    Gottlieb, A.
    Shah, K.
    Hu, C. C.
    Stevens, R.
    Day, R.
    Paul, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E145 - E146
  • [27] Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    M. Elaine Husni
    Atul Deodhar
    Sergio Schwartzman
    Soumya D. Chakravarty
    Elizabeth C. Hsia
    Jocelyn H. Leu
    Yiying Zhou
    Kim H. Lo
    Arthur Kavanaugh
    Arthritis Research & Therapy, 24
  • [28] Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    Husni, M. Elaine
    Deodhar, Atul
    Schwartzman, Sergio
    Chakravarty, Soumya D.
    Hsia, Elizabeth C.
    Leu, Jocelyn H.
    Zhou, Yiying
    Lo, Kim H.
    Kavanaugh, Arthur
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [29] ASSESSMENT OF DISABILITY LEVELS IN A COHORT OF 1,489 PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS, AND THE EFFECT OF APREMILAST TREATMENT: POOLED DATA FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS
    Mease, P. J.
    Wollenhaupt, J.
    Hall, S.
    Van den Bosch, F.
    Lespessailles, E.
    McIlraith, M.
    Teng, L.
    Edwards, C. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 354 - 354
  • [30] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial
    Kavanaugh, Arthur
    Mease, Philip J.
    Gomez-Reino, Juan J.
    Adewale, Adebajo
    Wollenhaupt, Juergen
    Hu, ChiaChi
    Stevens, Randall
    Cutolo, Maurizio
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (05) : 832 - 832
12345